Avenue Biosciences raises €4.8M Seed round
12 January 2026· Helsinki, Finland· health, biotechnology, drug_development, life_sciences, b2b, infrastructure, deep_hardware
To scale a high-throughput protein engineering tech that accelerates the discovery of protein-based therapies and tools for the BioTech industry.
Investors
LeadVoima Ventures
Also participating
BalnordTesiInventureDimerent
About Avenue Biosciences
Stage
Seed
Headquarters
Helsinki, Finland
Team Size
6–20
Sectors
healthbiotechnologydrug_developmentlife_sciencesb2binfrastructuredeep_hardware